Permanent Leadless Cardiac Pacing

Reddy, Vivek Y.; Knops, Reinoud E.; Sperzel, Johannes; Miller, Marc A.; Petrů, Jan; Šimon, J; Šedivá, Lucie; Groot, Joris R. de; Tjong, Fleur V.Y.; Jacobson, Peter; Ostrosff, Alan; Dukkipati, Srinivas R.; Koruth, Jacob S.; Wilde, Arthur A.M.; Kautzner, Josef; Neužil, Petr

doi:10.1161/circulationaha.113.006987

Cited by 256 publications

(116 citation statements)

References 24 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…Electrodes and leads, however, remain the weakest link which has led to the development of leadless pacemakers. (25) His bundle recording and EP studies…”

Section: Pacemakersmentioning

confidence: 99%

Rhythms of the heart: The history of electrophysiology and its current status in South Africa

Millar

Chin

2017

SAHJ

View full text Add to dashboard Cite

show abstract

“…Electrodes and leads, however, remain the weakest link which has led to the development of leadless pacemakers. (25) His bundle recording and EP studies…”

Section: Pacemakersmentioning

confidence: 99%

Rhythms of the heart: The history of electrophysiology and its current status in South Africa

Millar

Chin

2017

SAHJ

View full text Add to dashboard Cite

show abstract

“…However, main components of current pacemakers are still the same of the first cardiac pacemaker type, such as a pulse generator and one or more transvenous leads. This design usually causes some shortterm and long-term complications (in approximately 10% of patients) [4,20]. The subcutaneous pocket is very prone to local infections and often causes skin erosion and hematoma inside the implantation region [20].…”

Section: Leadless Cardiac Pacemaker (Lcp) As a New Minimal Invasive Mmentioning

confidence: 99%

“…In addition, implantation procedures of this regular pacemaker also have several risks. In the short-term, it can cause mobility limitations, pneumothorax, cardiac tamponade and upper limb Deep Vein Thrombosis (DVT) [3,4,6,19]. A study showed that up to six out of ten patients with regular pacemakers developed mobility limitations in the shoulder region, where the pulse generators were implanted [6].…”

Section: Leadless Cardiac Pacemaker (Lcp) As a New Minimal Invasive Mmentioning

confidence: 99%

See 1 more Smart Citation

Leadless Cardiac Pacemaker as a Novel Intervention Modality for Atrioventricular Conduction Disturbance in Hypertrophic Cardiomyopathy

Sutanto

2017

J.ATAMIS

View full text Add to dashboard Cite

Atrioventricular conduction disturbance is a common complication of cardiovascular diseases, such as hypertrophic cardiomyopathy. Moreover, the most common form of atrioventricular conduction disturbance is atrioventricular block. Until recently, cardiac pacing was considered to be the most reliable long-time management of atrioventricular block. However, cardiac pacemakers have several limitations and complications. When the first generation of leadless pacemakers was invented in the 1980s, it was multi-component. Nowadays, self-contained or single component leadless pacemakers have been developed and have become popular amongst cardiac electrophysiologists. In particular, in 2013, St. Jude Medical developed a novel design for a cardiac pacemaker called the NanostimTM Leadless Pacemaker. In 2015, Medtronic released a smaller leadless pacemaker called the MicraTM Transcatheter Pacing System.1,2 Although NanostimTM and MicraTM represent state of the art technology; a few studies have documented some of their limitations.3-6 More research is needed to confirm and solve these problems

show abstract

“…In addition, central lines (vascular catheters) should be avoided in patients with CIED devices, because they may be associated with higher risk of mortality from infection. 34 Leadless pacemaker technology provides an alternative that does not require pockets or leads 65,66,67 and therefore avoids many of the problems associated with intravascular lead use, including pocket infection. This represents an important therapeutic advance in suitable patients.…”

Section: Strategies To Prevent Cardiac Implantable Electronic Device mentioning

confidence: 99%

Cardiac Implantable Electronic Device Infection in Patients at Risk

Tarakji

Ellis

Defaye

et al. 2016

Arrhythmia &Amp; Electrophysiology Review

View full text Add to dashboard Cite

Device TherapyOver the last few decades an increasing body of evidence has supported the role of cardiovascular implantable electronic devices However, the cost and complications of device implantation, including infection or hardware malfunction in patients receiving CIEDs, have led to the concern that negative outcomes may partially counteract the expected benefits. The rate of CIED infection has been estimated at 0.5 % with primary implants and 1-7 % with secondary interventions.3,5-8 It is difficult to give accurate estimates of infection rates, given the fact that figures are partly based on retrospective series of varying duration, and that different definitions of infection exist. However, the incidence of CIED infection is increasing out of proportion to CIED implantation. 3,5,9 A US study reported a 12 % increase in the number of CIED implantations from 2004 to 2006, with a 57 % increment in CIED infections during the same period. 9Reasons for this rise in CIED infections include the fact that younger patients are receiving CIEDs, and therefore surviving long enough to require more pulse generator changes and lead revisions, which are associated with a higher infection rate. 7,10 In addition, there has been an increase in comorbidities, such as diabetes and kidney disease, resulting in poor wound healing and diminished immune responses. 3,9,11,12 Expanding indications for CIED use, coupled with an ageing population with more comorbidities, mean this trend is likely to increase.2 Better awareness and improved reporting of CIED infections may, however, help to decrease the higher complication rates noted in recent years.CIED infections also impose a substantial financial burden resulting from prolonged hospital stays, long duration of antibiotic therapy, management of sepsis and complications, device extraction and reimplantation.3 These infections typically cost at least $52,000 13 and may exceed $100,000. 14 This article will review strategies for management and prevention of CIED infections, including lead extraction and the use of an absorbable antibacterial envelope. Risk Factors for Cardiac Implantable Electronic Device Infections

show abstract

Permanent Leadless Cardiac Pacing

Abstract: http://clinicaltrials.gov. Unique identifier: NCT01700244.

Cited by 256 publications

References 24 publications

Rhythms of the heart: The history of electrophysiology and its current status in South Africa

Rhythms of the heart: The history of electrophysiology and its current status in South Africa

Leadless Cardiac Pacemaker as a Novel Intervention Modality for Atrioventricular Conduction Disturbance in Hypertrophic Cardiomyopathy

Cardiac Implantable Electronic Device Infection in Patients at Risk

Contact Info

Product

Resources

About